良好的開端遺傳學
遺傳學專家集合包含良好的開端
專家集合是analyst-curated列表,突出了公司你需要知道的最重要的技術空間。
良好的開端遺傳學中包含5專家集合,包括醫療設備。
醫療設備
8633件
公司發展醫療器械(每IMDRF的“醫療器械”的定義)。包括軟件、lab-developed測試(LDTs)和組合產品。*列更新盡可能經常。
組學
1267件
公司參與了捕獲、測序和/或分析基因組、轉錄組、蛋白質組學和/或代謝組學數據
數字醫療
10530件
數字健康收藏品包括供應商開發軟件、平台、傳感器和機器人硬件,在醫療健康數據基礎設施和tech-enabled服務。列表中不包括製藥/生物製藥、測序儀器,基因編輯和輔助技術。
它的健康
7901件
女性健康科技
480件
最新的良好的開端遺傳學新聞
2017年7月31日
17:15等分享這篇文章提供的消息,二。,July 31, 2017 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE: SFE ) today announced that its partner company, Good Start Genetics, Inc. ("Good Start"), signed a definitive agreement to be acquired by San Francisco-based genetics information company, Invitae Corporation (NYSE: NVTA ). The transaction is expected to close in the first part of August 2017, subject to customary closing conditions. Safeguard expects to receive initial consideration consisting of $3.8 million of Invitae common stock, based on the 30-day trailing average stock price, and an additional $1.3 million of Invitae common stock which will be held in escrow for up to 13 months. Invitae is one of the fastest growing genetic information companies in the U.S. whose longer-term strategy is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service comprising approximately 1,500 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, and other rare disease areas, as well as clinical analysis of a 20,000-gene medical exome. Stephen T. Zarrilli, Safeguard's President and CEO, said, "From Safeguard's perspective, this outcome represents a significant shortfall based on our return expectations. However, considering the anticipated time and cost required to introduce additional technologies and tests into adjacent markets and to further develop Good Start, we believe that a larger, more financially capable enterprise that is focused on genetic testing was necessary to move Good Start's vision forward." "Good Start is an excellent strategic fit with Invitae," said Gary J. Kurtzman, MD, Managing Director at Safeguard and board member at Good Start. "We believe that Invitae is the best partner to advance the mission Good Start began seven years ago." About Safeguard Scientifics Safeguard Scientifics (NYSE: SFE ) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Safeguard targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, please visit www.safeguard.com or follow us on Twitter @ safeguard . Forward-looking Statements Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the deployment of capital, the fact that our partner companies may vary from period to period, our substantial capital requirements and absence of liquidity from our partner company holdings, fluctuations in the market prices of our publicly traded partner company holdings, competition, our inability to obtain maximum value for our partner company holdings, our ability to attract and retain qualified employees, market valuations in sectors in which our partner companies operate, our inability to control our partner companies, our need to manage our assets to avoid registration under the Investment Company Act of 1940, and risks associated with our partner companies, including the fact that most of our partner companies have a limited history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's partner companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to predict or control. As a result of these and other factors, the Company's past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release. SAFEGUARD CONTACT: Senior Vice President, Investor Relations and Corporate Communications 610.975.4952
良好的開端遺傳學常見問題(FAQ)
良好的開端遺傳學的總部在哪裏?
良好的開端遺傳學的總部坐落在普特南大街237號,劍橋。
良好的開端遺傳學的最新一輪融資是什麼?
良好的開端遺傳學的最新一輪融資收購。
良好的開端遺傳學籌集了多少錢?
良好的開端遺傳學提出共60美元。
良好的開端遺傳學的投資者是誰?
投資者良好的開端遺傳學包括Invitae、環球化,維護科學,OrbiMed Advisors SV投資者和3更健康。
良好的開端遺傳學的競爭對手是誰?
良好的開端遺傳學的競爭對手包括Ativa醫療、AutoGenomics,牛津生物動力學,第三隻眼診斷,高潮生物科學和13。
比較好的開始遺傳學和競爭對手
珠峰新生兒聽力篩查設備,結合目前市場誘發耳聲排放和聽覺腦幹反應。公司總部位於聖路易斯,密蘇裏州,並正在開發一個手持,電池監控裝置使anesthetician知道什麼是發生在整個大腦,而病人麻醉。
Cervimark醫療診斷公司,正在開發一個篩選試驗預測早產的高危妊娠。測試是基於量化生物標誌物發現懷孕的患者的分泌物和關聯結果數據早產的風險。概念驗證對於這個測試已經證明在一個很小的人體試驗。
Ativa醫療是醫療診斷公司致力於提供診斷測試結果的時刻,而不是幾小時或幾天。
NeuroDx地址重要神經外科市場的未滿足的需求。ShuntCheck,他們的主要產品是一個援助的檢測offlow植入腦脊液(CSF)分流術。
Corp.m2m成像,在美國設有辦事處和澳大利亞生產的高清成像和工作流程解決方案生命科學應用MRI,寵物,CT和SPECT分析、臨床前和臨床研究環境。m2m的核磁共振線圈和附件包括產品組合,提供了解決方案,使在特定情況下的研究結果應用到世界各地。
新是一個分子診斷公司專注於發現、開發和商業化的非侵入性的基因表達檢測領域的移植醫學和自身免疫。每個公司,他們開發了一種專有的方法利用血液中基因表達,旨在為醫生提供一個新工具來管理心髒移植手術患者的護理。分子表達的新技術開發和實施正在探討心髒移植病人管理協助涉及免疫係統的其他疾病。